Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18176811 | 0.84 | TDP1 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1328516 | 0.83 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL2795678 | 0.83 | TDP1 (0.47) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL3683152 | 0.81 | TDP1 (0.44) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL4235641 | 0.80 | TDP1 (0.38) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL895070 | 0.80 | TDP1 (0.53) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL500234 | 0.79 | TDP1 (0.55) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21887790 | 0.79 | MEN1 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL31270901 | 0.78 | CA12 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL20524433 | 0.78 | KMT2A (0.38) | MEN1KMT2AGAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4655302-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | The University of North Carolina at Chapel Hill (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025244832-A1 | NOVEL AMINOGUANIDINE DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | KONG'S PHARMACEUTICAL CO. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4562001-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-20 | — | — | US | disclosed |
| CN-1440385-A | Pyrrole derivatives for the treatment of AIDS | HOFFMANN LA ROCHE (CH) | 2003-09-03 | — | — | CN | disclosed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1301481-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-6534530-B1 | Administering (benzo)thiazole peptidomimetic as viricide; protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| WO-2003013526-A1 | ANTICOAGULANT COMPOUNDS | MERCK & CO. INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1242426-A1 | GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020032221-A1 | Pyrrole derivatives | ROCHE PRODUCTS LIMITED (GB) | 2002-03-14 | — | — | US | disclosed |
| WO-2002002524-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001038332-A1 | GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304912-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | TDP1 1065/4885MAOA 1519/4885MAOB 1093/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | TDP1 388/4885MAOA 1338/4885MAOB 1041/4885 |
| US-20020032221-A1 | Pyrrole derivatives | PYCR1, SARS1, MAVS | TDP1 990/4885MAOA 3894/4885MAOB 3193/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | TDP1 2647/4885MAOA 155/4885MAOB 106/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TDP1 1053/4885MAOA 2014/4885MAOB 2819/4885 |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, NRAS, RAF1 | TDP1 2146/4885MAOA 1727/4885MAOB 1184/4885 |
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | TDP1 281/4885MAOA 288/4885MAOB 203/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | TDP1 1641/4885MAOA 545/4885MAOB 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.